Clinical trial · Interventional
Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Patients With Unresectable Hepatocellular Carcinoma: a Prospective, Open, Randomized Controlled Trial
NCT06749678CI-TRIAL-00084083not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, randomised controlled clinical trial to study the impact of prehabilitation on postoperative complications, physical function, quality of life, and short-term survival outcomes in patients with unresectable liver cancer undergoing conversion therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Prehabilitation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prehabilitation | Behavioral | — | UNRESOLVED |
| Routine nursing measures | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Prehabilitation group
- description
- In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period.
- interventionNames
- Behavioral: Prehabilitation
- Behavioral: Routine nursing measures
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- During the conversion therapy period, the control group only took routine nursing measures.
- interventionNames
- Behavioral: Routine nursing measures
Primary outcomes (1)
- measure
- Complication Composite Index (CCI) at 30 days postoperatively
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must be aged between 18 and 75 years, inclusive, with no gender restrictions. 2. Patients must have an initial diagnosis of unresectable hepatocellular carcinoma (HCC) confirmed by EASL/AASLD diagnostic criteria, pathological histology, or cytology, and must be planned for conversion therapy. 3. Patients must have an American Society of Anesthesiologists (ASA) physical status classification of ≤III. 4. Patients must be physically capable of participating in exercise training, defined as the ability to walk continuously on flat ground for more than 200 meters without rest and to climb two flights of stairs consecutively without requiring a break. 5. Patients must not have any psychiatric disorders, speech impediments, or consciousness disturbances, and must possess adequate comprehension, communication, and literacy skills. 6. Patients must voluntarily enroll in the study, be able to provide written informed consent, and be capable of understanding and adhering to the trial protocol and follow-up procedures. \- Exclusion Criteria: 1. A known diagnosis of cholangiocarcinoma, sarcomatoid hepatocellular carcinoma (HCC), combined hepatocellular carcinoma, or fibrolamellar carcinoma. 2. Presence of extrahepatic metastases or concurrent other malignant tumors. 3. Presence of psychiatric disorders or cognitive impairments that would impede compliance with study requirements. 4. Unsuitability for participation in exercise training due to skeletal muscle diseases or a history of fracture within the past 6 months. 5. Pregnant or breastfeeding women. 6. Individuals with severe and irreversible cardiac, pulmonary, or renal organic diseases, or severe anemia, which would make them unsuitable for preoperative rehabilitation programs. -
References
Publications (0)
Data not yet available
No reference posted for this study.